Vis enkel innførsel

dc.contributor.authorLøken-Amsrud, Kristin Ingeleiv
dc.contributor.authorMyhr, Kjell-Morten
dc.contributor.authorBakke, Søren Jacob
dc.contributor.authorBeiske, Antonie Giæver
dc.contributor.authorBjerve, Kristian S
dc.contributor.authorBjørnarå, Bård T.
dc.contributor.authorHovdal, Harald Olav
dc.contributor.authorLilleås, Finn
dc.contributor.authorMidgard, Rune
dc.contributor.authorPedersen, Tom
dc.contributor.authorSaltyte Benth, Jurate
dc.contributor.authorTorkildsen, Øivind
dc.contributor.authorWergeland, Stig
dc.contributor.authorHolmøy, Trygve
dc.identifier.citationPLoS ONE 2013, 8(1)nb_NO
dc.description.abstractObjective: Alpha-tocopherol is the main vitamin E compound in humans, and has important antioxidative and immunomodulatory properties. The aim of this study was to study alpha-tocopherol concentrations and their relationship to disease activity in Norwegian multiple sclerosis (MS) patients. Methods: Prospective cohort study in 88 relapsing-remitting MS (RRMS) patients, originally included in a randomised placebo-controlled trial of omega-3 fatty acids (the OFAMS study), before and during treatment with interferon beta. The patients were followed for two years with repeated 12 magnetic resonance imaging (MRI) scans and nine serum measurements of alpha-tocopherol. Results: During interferon beta (IFNB) treatment, each 10 µmol/L increase in alpha-tocopherol reduced the odds (CI 95%) for simultaneous new T2 lesions by 36.8 (0.5–59.8) %, p = 0.048, and for combined unique activity by 35.4 (1.6–57.7) %, p = 0.042, in a hierarchical regression model. These associations were not significant prior to IFNB treatment, and were not noticeably changed by gender, age, body mass index, HLA-DRB1*15, treatment group, compliance, or the concentrations of 25-hydroxyvitamin D, retinol, neutralising antibodies against IFNB, or the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid. The corresponding odds for having new T1 gadolinium enhancing lesions two months later was reduced by 65.4 (16.5–85.7) %, p = 0.019, and for new T2 lesions by 61.0 (12.4–82.6) %, p = 0.023. Conclusion: During treatment with IFNB, increasing serum concentrations of alpha-tocopherol were associated with reduced odds for simultaneous and subsequent MRI disease activity in RRMS patients.nb_NO
dc.publisherPublic Library of Sciencenb_NO
dc.rightsNavngivelse 3.0 Norge*
dc.titleAlpha-tocopherol and MRI outcomes in multiple sclerosis - association and predictionnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.subject.nsiVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Nevrologi: 752nb_NO
dc.subject.nsiVDP::Midical sciences: 700::Clinical medical sciences: 750::Neurology: 752nb_NO
dc.source.journalPLoS ONEnb_NO
dc.description.localcode© 2013 Løken-Amsrud et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.nb_NO

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 3.0 Norge
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 3.0 Norge